A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Rapamycin is a drug that has been approved by the Food and Drug Administration (government)
for use in patients receiving a kidney transplant to prevent the patient's body from
rejecting the transplanted kidney. It has shown antitumor effects in the laboratory, but has
not been approved at this time for the treatment of cancer. Abraxane is a new form of
chemotherapy that has been approved by the Food and Drug Administration for the treatment of
metastatic breast cancer, and is a promising drug that is being evaluated in clinical trials
for treatment of other cancers. This is a phase I study designed to find out if different
doses of Rapamycin, when combined with Abraxane, are safe and well tolerated.